New GLP-1 Indications in 2026: Sleep Apnea, Fatty Liver, and Fertility

GLP-1 medications, originally known as allies in controlling diabetes and weight, gained ground in 2026 with three new indications that promise to change the lives of millions of people. Sleep apnea, metabolically associated fatty liver disease (MASH), and fertility. For each of these conditions, science brought concrete data that expands the range of use of these drugs.

What Is GLP-1 and Why Did It Become So Well Known

GLP-1 (glucagon-like peptide-1) is an intestinal hormone that acts on the regulation of appetite and blood sugar. Since synthetic versions entered the market, first for diabetes and then for obesity, the medical community began investigating its effects on other body systems. What was discovered in recent years goes far beyond the scale.

These medications mimic the action of the natural hormone, reducing hunger, improving blood sugar control, and, as a positive side effect, influencing inflammatory and metabolic processes in several organs. This is why researchers started testing them in conditions beyond weight and blood sugar.

Sleep Apnea: The Connection to Weight

Obstructive sleep apnea happens when the throat muscles relax too much during rest and block the airways. The result is fragmented sleep, intense snoring, and, in the long term, a higher risk of cardiovascular problems. The relationship with excess weight is well established: fat around the upper airways contributes directly to narrowing.

The most recent clinical trials with GLP-1 demonstrated significant reductions in apnea severity. Patients who used semaglutide for six months showed a decrease in respiratory event index per hour of sleep, something no specific medication for apnea had managed to achieve until now. Weight loss reduces pressure on the airways, and the anti-inflammatory effect of GLP-1 helps improve local muscle tone.

Fatty Liver: When the Organ Accumulates Too Much Fat

Metabolic hepatic steatosis, previously called NASH and now designated MASH (metabolic alcohol-free steatohepatitis), occurs when the liver accumulates fat excessively with no relation to alcohol consumption. This is a condition that can progress to fibrosis, cirrhosis, and, in the most severe cases, the need for a transplant.

Here too, GLP-1s showed encouraging results. Phase 3 studies with semaglutide and tirzepatide indicated resolution of liver inflammation in a significant proportion of participants. Reduction of fat in the liver occurred even in patients who did not have such pronounced weight loss, which suggests a direct effect of the medication on the organ's cellular metabolism.

Diagnosis is usually made through ultrasound or elastography, often as an incidental finding during routine exams. People with pre-diabetes, type 2 diabetes, or insulin resistance are in the highest-risk group.

Fertility: What Science Already Knows

The relationship between GLP-1 and fertility is still in an earlier stage, but the data is promising. In women with polycystic ovary syndrome (PCOS), a condition frequently associated with insulin resistance and excess weight, the use of these medications was linked to improved menstrual regularity and higher ovulation rates.

Men can also benefit. Male infertility is connected to metabolic and inflammatory changes, and the positive effects of GLP-1 on body composition and systemic inflammation may contribute to improved semen quality.

The proposed mechanism involves the reduction of low-grade chronic inflammation and improved insulin sensitivity, factors that directly interfere with reproductive function. Long-term studies are still needed to understand the full impact, but the direction of the data is favorable.

What This Changes in Practice

These three new indications expand the profile of who can benefit from GLP-1s. Previously restricted to patients with diabetes or severe obesity, these medications now present themselves as an option for people who suffer from weight-related sleep apnea, fatty liver disease in early or moderate stage, and reproductive difficulties associated with metabolic issues.

Medical follow-up remains indispensable. These drugs are not cosmetics and require clinical evaluation, periodic exams, and dose adjustment. Use must be done with a prescription and regular monitoring.

For those seeking support in organizing health information, monitoring habits, and tracking treatment, dedicated apps can work as a useful complement. By clicking here you can access a tool that helps you understand how your body responds to treatment and keep a record of changes over time. Ozempro lets you log symptoms, track weight and metabolic indicators, and organize everything simply so you can bring the information to your next appointment.

The future of metabolic treatment is becoming increasingly integrated. Medications that act on multiple biological pathways, accompanied by digital tools that assist in daily life, represent a real shift in how we take care of health.

The advances of 2026 confirm something medicine has been observing: the human body does not function in separate compartments. What affects the liver influences sleep. What improves metabolism helps fertility. GLP-1s are at the center of this broader vision, and the new indications are just the beginning.